Literature DB >> 23838731

Clostridium difficile infection in pediatric acute myeloid leukemia: from the Canadian Infections in Acute Myeloid Leukemia Research Group.

Victoria Price1, Carol Portwine, Shayna Zelcer, Marie-Chantal Ethier, Biljana Gillmeister, Mariana Silva, Christina Schindera, Rochelle Yanofsky, David Mitchell, Donna L Johnston, Victor Lewis, David Dix, Sonia Cellot, Bruno Michon, Lynette Bowes, Kent Stobart, Josee Brossard, Joseph Beyene, Lillian Sung.   

Abstract

BACKGROUND: The prevalence and severity of Clostridium difficile infection (CDI) has increased over time in adult patients, but little is known about CDI in pediatric cancer. The primary objectives were to describe the incidence and characteristics of CDI in children with de novo acute myeloid leukemia (AML). The secondary objective was to describe factors associated with CDI.
METHOD: We performed a multicenter, retrospective cohort study of children with de novo AML and evaluated CDI. Recurrence, sepsis and infection-related death were examined. Factors associated with CDI were also evaluated.
RESULTS: Forty-three CDI occurred in 37 of 341 (10.9%) patients during 42 of 1277 (3.3%) courses of chemotherapy. There were 6 children with multiple episodes of CDI. Three infections were associated with sepsis, and no children died of CDI. Only 2 children had an associated enterocolitis. Both days of broad-spectrum antibiotics (odds ratio 1.03, 95% confidence interval: 1.01 to 1.06; P = 0.003) and at least 1 microbiologically documented sterile site infection (odds ratio 10.81, 95% confidence interval: 5.88 to 19.89; P < 0.0001) were independently associated with CDI.
CONCLUSIONS: CDI occurred in 11% of children receiving intensive chemotherapy for AML, and outcomes were not severe. CDI is not a prominent issue in pediatric AML in terms of prevalence, incidence or associated outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23838731     DOI: 10.1097/INF.0b013e31828690a4

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Authors:  Yilun Sun; Rachael L Huskey; Li Tang; Hiroto Inaba; Aditya H Gaur; Raul Ribeiro; Jeffrey E Rubnitz; Joshua Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.

Authors:  Shane J Cross; Theodore H Morton; Joshua Wolf
Journal:  J Pediatric Infect Dis Soc       Date:  2021-11-17       Impact factor: 3.164

3.  Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated Clostridium difficile Infection in Children.

Authors:  Zachary I Willis; Maribeth R Nicholson; Adam J Esbenshade; Meng Xu; James C Slaughter; Debra L Friedman; Kathryn M Edwards; Maria C Di Pentima
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

4.  Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Authors:  Bryan T Nycz; Samuel R Dominguez; Deborah Friedman; Joanne M Hilden; Diana Ir; Charles E Robertson; Daniel N Frank
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

5.  Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia.

Authors:  Ditte J A Løhmann; Peter H Asdahl; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Gertjan J L Kaspers; Minna Koskenvuo; Birgitte Lausen; Barbara De Moerloose; Josefine Palle; Bernward Zeller; Lillian Sung; Henrik Hasle
Journal:  Cancer Med       Date:  2019-09-18       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.